By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Gentronix today said that it has signed a three-year deal with GlaxoSmithKline, under which it will provide the drug maker with its GeneScreen HC and BlueScreen HC genotoxicity assays.

The Manchester, UK-based assay developer said that the agreement extends a pact with GSK for the GreenScreen HC to include the BlueScreen HC in 384-well format, which is its latest human cell reporter-based assay for compound profiling.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.